Delivery Order SPE2DB22D9304-SPE2DB24FSSL4

Award Date 1/22/24
Potential Completion Date 2/12/24
Potential Value $3.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The order, valued at $6,189.60, is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGE. The delivery order was issued against an existing indefinite delivery contract held by DMS Pharmaceutical Group with DLA to provide a variety of pharmaceutical and medical supplies to military treatment facilities worldwide. The contract has a potential...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the supply of XOLAIR 150 MG/ML SYRINGEML, with a potential value of $7,737.00. The contract has a completion date of February 2, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a wide range of brand and generic prescription and over-the-counter drug supplies to the federal...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a potential value of $58,027.50 and a completion date of January 23, 2024. DMS Pharmaceutical Group will provide Xolair 150 mg/mL syringes to support DLA Troop Support Medical facilities. This delivery order is part of a larger indefinite delivery contract held by DMS Pharmaceutical Group to provide a variety of...
The Department of Defense's Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide XOLAIR 150 mg/ml syringes. The $123,792.00 delivery order has an estimated completion date of April 3, 2023. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that holds various indefinite delivery contracts with DLA to supply a wide range of pharmaceutical and medical products to military treatment...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the provision of the pharmaceutical product XOLAIR 75 mg/0.5 ml syringe 0.5 ml, with a potential value of $2,707.95 and a completion date of January 17, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that holds various federal contracts and indefinite delivery vehicles (IDVs) to...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGE and has a potential value of $10,831.80. The order has a completion date of February 1, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a variety of brand and generic prescription and over-the-counter drug supplies to the federal...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide XOLAIR 150 MG/ML SYRINGE 1 ML. The delivery order, valued at $23,211.00, is part of a larger indefinite delivery contract with DLA Troop Support Medical that provides a variety of pharmaceutical and medical products to support military treatment facilities worldwide. The delivery order has a completion date of February 12, 2024. DMS...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to DMS Pharmaceutical Group Inc., a woman-owned small business. The $1,547.40 contract is for the delivery of XOLAIR 150 MG/ML SYRINGEML, with a completion date of February 21, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a wide range of brand and generic prescription and over-the-counter drug supplies to U.S. government agencies,...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is to provide the pharmaceutical product XOLAIR 150 MG/ML SYRINGE with a potential value of $3,094.80 and a completion date of February 9, 2024. This delivery order is issued against DMS Pharmaceutical Group's existing indefinite delivery contract with DLA to provide various pharmaceutical and medical supplies...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide the pharmaceutical product XOLAIR 150 MG/ML SYRINGE. The contract has a potential value of $14,700.32 and a completion date of March 1, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that supplies a wide range of branded and generic pharmaceuticals to U.S. government agencies,...
  • SPE2DB22D9304
    Indefinite Delivery Contract
  • SPE2DB22D9304-SPE2DB24FSSL4
    Delivery Order

This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is to provide XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product, with a potential value of $3,094.80 and a completion date of February 12, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that holds numerous contracts and indefinite delivery vehicles (IDVs) with DLA to supply a wide range of pharmaceuticals and medical products to military treatment facilities worldwide. This delivery order is issued against one of those existing IDVs with DLA, which can have a potential value of up to $5 million through December 2025.

Generated 4/22/24, 9:48 AM